参考文献/References:
[1] Goodenberger ML, Jenkins RB. Genetics of adult glioma [J].
Cancer Genet. 2012, 205(12): 613-621.
[2] 《中国中枢神经系统胶质瘤诊断和治疗指南》编写组. 中
国中枢神经系统胶质瘤诊断与治疗指南（2015）[J]. 中华
医学杂志，2016，96（7）：485-509.
[3] Parsons DW, Jones S, Zhang X, et al. An integrated genomic
analysis of human glioblastoma multiforme [J]. Science,
2008, 321: 1807-1812.
[4] Visani M, Acquaviva G, Marucci G, et al. Non-canonical
IDH1 and IDH2 mutations: a clonal and relevant event in
an Italian cohort of gliomas classified according to the
2016 World Health Organization (WHO) criteria[J]. J
Neurooncol, 2017, 135(2): 245-254.
[5] Hartmann C, Hentschel B, Wick W, et al. Patients with
IDH1 wild type anaplastic astrocytomas exhibit worse
prognosis than IDH1-mutated glioblastomas, and IDH1
mutation status accounts for the unfavorable prognostic
effect of higher age: implications for classification of
gliomas [J]. Acta neuropathol, 2010, 120(6): 707-718.
[6] Noushmehr H, Weisenberger DJ, Diefes K, et al. Identifica-
tion of a CpG island methylator phenotype that defines a
distinct subgroup of glioma [J]. Cancer Cell, 2010, 17(5):
510-522.
[7] Cen L, Carlson BL, Schroeder MA, et al. p16-Cdk4-Rb axis
controls sensitivity to a cyclin-dependent kinase inhibitor
PD0332991 in glioblastoma xenograft cells [J]. Neuro
Oncol, 2012, 14(7): 870-881.
[8] Juratli TA, Lautenschl?ger T, Geiger KD, et al. Radio-
chemotherapy improves survial in IDH-mutant, 1p/19q
non-codeleted secondary high-grade astrocytoma patients
[J]. J Neurooncol, 2015, 124(2): 197-205.
[9] Wang L, Li Z, Liu C, et al. Comparative assessment of three
methods to analyze MGMT methylation status in a series of
350 gliomas and gangliogliomas [J]. Pathol Res Pract,
2017, 213(12): 1489-1493.
[10] Lee A, Youssef I, Osborn VW, et al. The utilization of
MGMT promoter methylation testing in United States
hospitals for glioblastoma and its impact on prognosis [J]. J
Clin Neurosci, 2018, 51(5): 85-90.
[11] Reifenberger J, Reifenberger G, Liu L, et al. Molecular
genetic analysis of oligodendroglial tumors shows preferen-
tial allelic deletions on 19q and 1p [J]. Am J Pathol, 1994,
145(5): 1175-1190.
[12] 崔向丽，赵志刚，任晓辉，等. 胶质瘤染色体1p/19q联合
缺失特点分析[J]. 中华外科杂志，2010，48（11）：852-855.
[13] van den Bent MJ, Weller M, Wen PY, et al. A clinical pers-
pective on the 2016 WHO brain tumor classification and
routine molecular diagnostics [J]. Neuro Oncol, 2017, 19(5):
614-624.
[14] Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter muta-
tions occur frequently in gliomas and a subset of tumors
derived from cells with low rates of self renewal [J]. Proc
Natl Acad Sci USA, 2013, 10(15): 6021-6026.
[15] Eckel-Passow JE, Lachance DH, Molinaro AM, et al.
Glioma groups based on 1p/19q, IDH, and TERT promoter
mutations in tumors [J]. N Engl J Med, 2015, 372(26):
2499-2508.
[16] Labussiere M, Di Stefano AL, Gleize V, et al. TERT promo-
ter mutations in gliomas, genetic associations and clinico-
pathological correlations [J]. Br J Cancer， 2014, 111(10):
2024-2032.
[17] Kosty J, Lu F, Kupp R, et al. Harnessing OLIG2 function in
tumorigenicity and plasticity to target malignant gliomas [J].
Cell Cycle, 2017, 16(8): 1654-1660.
[18] Durand K S, Guillaudeau A, Weinbreck N, et al. 1p19q
LOH patterns and expression of p53 and Olig2 in gliomas,
relation with histological types and prognosis [J]. Modern
Pathol, 2010, 23(4): 619-628.
[19] Takami H, Yoshida A, Fukushima S, et al. Revisiting TP53
mutations and immunohistochemistry-a comparative study
in 157 diffuse gliomas [J]. Brain Pathol, 2015, 25: 256-265.
[20] Yao TW, Zhang J, Prados M, et al. EGFR blockade prevents
glioma escape from BRAFV600E, targeted therapy [J].
Oncotarget, 2015, 6(26): 21993-22005.
[21] Stec W, Rosiak K, Treda C, et al. Cyclictrans- phosphory-
lation in a homodimer as the predominant mechanism of
EGFRvⅢ action and regulation [J]. Oncotarget, 2018, 9(9):
8560-8572.
[22] Montano N, Cenci T, Martini M, et al. Expression of EGFR
Ⅷ in glioblastoma, prognostic significance revisited [J].
Neoplasia, 2011, 13(12): 1113-1121.
相似文献/References:
[1]王振宇.脊髓髓内肿瘤诊断与治疗中若干问题的讨论[J].中国临床神经外科杂志,2015,(11):641.[doi:10.13798/j.issn.1009-153X.2015.11.001]
[2]王在贵 张新元 杨 铭 潘 力 李国栋 刘 征 伍 杰 马廉亭.MRI、320-CTA及DSA在脊髓血管病诊断中的应用[J].中国临床神经外科杂志,2015,(11):643.[doi:10.13798/j.issn.1009-153X.2015.11.002]
WANG Zai-gui,ZHANG Xin-yuan,YANG Ming,et al.Value of MRI, 320-CTA and DSA to diagnosis of spinal vascular disease[J].,2015,(09):643.[doi:10.13798/j.issn.1009-153X.2015.11.002]
[3]于 涛 黄正通 王振宇.椎管内脊膜囊肿的临床特征和治疗方法[J].中国临床神经外科杂志,2015,(11):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
YU Tao,HUANG Zheng-tong,WANG Zhen-yu.Clinical features and treatment of intraspinal arachnoid cysts[J].,2015,(09):654.[doi:10.13798/j.issn.1009-153X.2015.11.005]
[4]柳 羲 张 帆 田勤力 刘 利.成人幕上原始神经外胚层肿瘤3例报道及文献复习[J].中国临床神经外科杂志,2015,(11):689.[doi:10.13798/j.issn.1009-153X.2015.11.016]
[5]刘 阳 连 伟 综述 王任直 校审.垂体泌乳素腺瘤诊疗中常见问题及解决方案[J].中国临床神经外科杂志,2015,(11):698.[doi:10.13798/j.issn.1009-153X.2015.11.020]
[6]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(09):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[7]敖祥生 胡克琦.血管内治疗椎动脉夹层动脉瘤14例临床分析[J].中国临床神经外科杂志,2016,(05):302.[doi:10.13798/j.issn.1009-153X.2016.05.016]
[8]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[9]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(09):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[10]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(09):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[11]杨佃旭 徐志明 李晓梅 王丽丽 王桂松.突入桥小脑角区胶质瘤的诊治分析（附5例报告）[J].中国临床神经外科杂志,2016,(03):171.[doi:10.13798/j.issn.1009-153X.2016.03.014]
[12]赵建辉 胡世颉 综述 费 舟 审校.miRNA在胶质瘤临床诊疗中的研究进展[J].中国临床神经外科杂志,2016,(10):642.[doi:10.13798/j.issn.1009-153X.2016.10.029]